Ensysce Biosciences (ENSC) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($10.3 million vs $10.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | TOVX |
|---|---|---|
| Share price | $0.527 | $0.217 |
| Market cap | $10.25M | $9.96M |
| 1-day change | +15.07% | -4.45% |
| YTD return | — | +8.14% |
| 1-year return | — | -49.53% |
| 5-year return | — | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-2.47 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $0.86 |
| 52-week low | $0.23 | $0.16 |
| Distance from 52-week high | -80.84% | -74.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +1465.46% | +1052.07% |
| Average volume | 14.21M | 525.96K |
| Shares outstanding | 19.46M | 45.89M |
| Employees | 8 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ENSC vs TOVX FAQ
Which is bigger, Ensysce Biosciences or Theriva Biologics?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $10.25M compared with $9.96M for Theriva Biologics (TOVX).
Are Ensysce Biosciences and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.